Signalling Pathways 2019: Programme

The ESMO Symposium on Signalling Pathways 2019 programme is now available online

The 7th edition of the ESMO Symposium on Signalling Pathways in Cancer, in partnership with the European Association for Cancer Research (EACR), focused on Gene fusions.

Gene fusions and rearrangements are now known to be important in oncogenesis and open a new avenue in Precision Medicine development with drugs of proven efficacy in selected tumours harbouring predictive biomarker such as gene fusions or rearrangements.

The ESMO Signalling Pathway symposium 2019 will be the subject of  “Gene fusion: from gene architecture evolution to cell addiction and therapeutic opportunities”.

View programme online

This symposium is an excellent opportunity to have a global overview on gene fusion from the discovery to clinical applications and to bridge Basic, Translational and Clinical Research for their implementation in clinical practice.

Learning objectives

This symposium dedicated to Basic Scientists, Translational Researchers and Medical Oncologists will offer an opportunity to:

  • Understand the basic genetic mechanisms of gene fusion
  • Look at gene fusion as a potential target in cancer characterisation and treatment
  • Discuss issues of testing in a low-prevalence, trans-tumour agnostic setting type of approach
  • Update your knowledge with the various tumours and gene fusion presently targeted along with treatment outcome in recent clinical trials

Accreditation

ESMO-MORA: The Symposium programme is going to be accredited with ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification also guarantees that a certified medical oncologist has continued to update her/his knowledge and continue to possess the necessary skills and standards for the practice of medical oncology.   See here for further details.